| First Author | Hayashi Y | Year | 2019 |
| Journal | Am J Pathol | Volume | 189 |
| Issue | 4 | Pages | 900-910 |
| PubMed ID | 30653955 | Mgi Jnum | J:318891 |
| Mgi Id | MGI:6863613 | Doi | 10.1016/j.ajpath.2018.12.005 |
| Citation | Hayashi Y, et al. (2019) Galectin-3 Inhibits Cancer Metastasis by Negatively Regulating Integrin beta3 Expression. Am J Pathol 189(4):900-910 |
| abstractText | Galectin-3 (Gal-3; gene LGALS3) is a member of the beta-galactose-binding lectin family. Previous studies showed that Gal-3 is expressed in several tissues across species and functions as a regulator of cell proliferation, apoptosis, adhesion, and migration, thus affecting many aspects of events, such as angiogenesis and tumorigenesis. Although several reports have suggested that the level of Gal-3 expression correlates positively with tumor progression, herein we show that highly metastatic mouse melanoma B16/BL6 cells express less Gal-3 than B16 cells with a lower metastatic potential. It was found that overexpression of Gal-3 in melanoma cells in fact suppresses metastasis. In contrast, knocking out Gal-3 expression in cancer cells promoted cell aggregation mediated through interactions with platelets and fibrinogen in vitro and increased the number of metastatic foci in vivo. Thus, reduced Gal-3 expression results in the up-regulation of beta3 integrin expression, and this contributes to metastatic potential. These findings indicate that changes of Gal-3 expression in cancer cells during tumor progression influence the characteristics of metastatic cells. |
